Table 1 Trials' Characteristics
| Authors | Pts | Prior chemotherapy lines for metastatic disease | Arms | > 3 sites | No adjuvant Chemo | Visceral site | Hormonal Receptors Negative (RN) | Prior taxanes (T) | Prior Anthra (A) |
|---|---|---|---|---|---|---|---|---|---|
| Miller et al | 462 | Mostly 1-2 |
Cap (2,500 mg/m2/day, days 1-14) Cap (2,500 mg/m2/day, days 1-14) + Beva (15 mg/kg) | 49.7% | NR | 78.7% | NR | 100% | 100% |
| Gray et al | 722 | 0 | wPac (90 mg/m2 day 1, 8 and 15)wPac (90 mg/m2 day 1, 8 and 15)+ Beva (10 mg/kg) | 45.7% | 34.2% | 62.2% | 36.7% | 14.9% | 37.2% |
| Miles et al | 736 | 0 |
Doc (100 mg/m2) Doc (100 mg/m2)+ Beva 7.5 (7.5 mg/kg) Doc (100 mg/m2)+ Beva 15 (15 mg/kg) |
35.0% 33.4% |
54.8% 54.9% | NR |
17.1% 17.1% |
14.9% 16.2% |
53.7% 53.5% |
| Dieras et al | 622 615 | 0 |
A/T A/T + Beva (15 mg/kg) Cap (2,000 mg/m2/day, days 1-14) Cap (2,000 mg/m2/day, days 1-14) + Beva (15 mg/kg) |
54.5% 27.8% |
45.2% 43.9% |
70.4% 68.8% |
24.0% 23.6% |
15.0% 39.5% |
29.9% 62.9% |
| Bruwski et al | 684 | 1 |
Chemo Chemo + Beva | 45.3% | NR | 73.1% | 27.7% | NR | NR |